The Racehorse Medication and Testing Consortium formed earlier this year has incorporated as a charitable organization and issued its goals and objectives, one of which has been broadened to include the auction and training aspects of the Thoroughbred business.
The chairman of the Kentucky Racing Commission said Sept. 13 he hopes a revised race-day medication policy for the Bluegrass state becomes a model for the rest of the country as it pushes toward uniformity in racehorse medication and drug testing.
Horsemen, veterinarians, racing officials, and regulators in Kentucky have been working behind the scenes to develop a new medication policy for the state that figures to greatly influence the debate over a uniform medication policy for the United States.
As the Racing Medication and Testing Consortium continues its march toward uniformity in Thoroughbred racing, battle lines are being formed by other groups that believe a furosemide-only policy on race days is too extreme.
Representatives of 15 Thoroughbred, Quarter Horse, and Standardbred organizations will meet May 1 at a by-invitation-only meeting to implementation of recommendations on drug-testing, medication, security, and enforcement.
The Kentucky Horsemen's Benevolent and Protective Association is polling horsemen to get their opinions on the state's medication policies, which include a ban on all Class 1, 2, and 3 drugs within 48 hours of a race, and use of anti-inflammatory anti-bleeding medications on race day.
A panel discussion on medication use and regulations in the pari-mutuel industry will be part of an equine medical symposium hosted by the University of Florida College of Veterinary Medicine March 14-15 in Hollywood Beach, Fla.
In the wake of a Jan. 28 teleconference to discuss plans for a national medication policy, organizers and the National Horsemen's Benevolent and Protective Association continue to negotiate on a representation issue.
Representatives from about 20 industry organizations unanimously endorsed a plan to develop a national medication policy during a teleconference Jan. 28. The action followed the first Racehorse Medication Summit, held Dec. 4, 2001, in Tucson, Ariz.
The board of the National Horsemen's Benevolent and Protective Association, during its winter convention in Las Vegas, Nev., Jan. 22-24, passed two motions tied to medication issues: One calls for more representation in follow-up meetings to the Racehorse Medication Summit, while the other seeks official positions from affiliates on use of race-day therapeutic medication.
Uniformity among testing procedures and the development of a broad-based funding mechanism to support expanded testing programs and research were among 21 recommendations made by Racehorse Medication Summit report released today.
The official report on the Dec. 4 Racehorse Medication Summit organized by the American Association of Equine Practitioners could be released Jan. 4. The document is expected to provide information on consensus reached by the more than 30 industry officials who participated.
The second round of "super-test" results from the National Thoroughbred Racing Association Racing Integrity and Drug Testing Task Force should be released early in January, said Jim Gallagher, executive director of the task force.
In the aftermath of Tuesday's Racehorse Medication Summit, it was all about time and money. Participants said they wouldn't have much more to say until the official minutes of the meeting are released, and that the success of any proposal hinges on a funding mechanism.
Participants at Tuesday's Racehorse Medication Summit in Tucson, Ariz., reached a consensus on medication, drug-testing, security, and enforcement, but said much of any future policy depends on scientific determinations. The group of about 30 industry officials did agree on the need for a uniform medication policy and decision levels for therapeutic medications, but specifics weren't discussed.
Racing industry participants expressed hope Tuesday morning that a five-hour facilitated session on medication would at least serve as a starting point toward uniformity. No one expected radical changes in current policies that vary by jurisdiction in the United States.